Investor Eye: Novalis Embraces Early Investment And Enabling Technology

Novalis Biotech employs early targeted investments to produce returns, focusing on enabling technologies and risky ventures in diagnostics and digital health.

Investor Eye Fetaure Image

Novalis Biotech is a venture capital group focused on seed-stage bioinformatics, diagnostics, digital health, and genomics companies with an emphasis on critical future growth areas.

Novalis was founded by Jan Van den Berghe and Wim Van Criekinge in 2018. Since then, it closed its first fund, Novalis Biotech Acceleration (Fund I). That fund, which raised a total of $4.7m, invested in eight small biotech and digital health companies, predominantly within the Benelux region

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Investor Eye

More from Business